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ABSTRACT
Background: The carnitine O-palmitoyltransferase I (EC 2.3.1.21)
inhibitor etomoxir inhibits fatty acid oxidation, and hepatic fatty
acid oxidation has been suggested to be a metabolic satiety sig-
nal in subjects who consume high-fat diets.
Objective: We investigated substrate oxidation and satiety after
repeated administrations of etomoxir or placebo in subjects who
consumed a high-fat diet.
Design: In a randomized crossover design consisting of three 5-d
treatments, we fed 10 healthy men [mean ± SE age: 25.6 ± 1.7 y;
mean ± SE body mass index (in kg/m2): 21.8 ± 0.3] a high-fat
diet twice and a low-fat diet once. The subjects consumed each
diet at home for 3 consecutive days, after which they spent 36 h
in energy balance in a respiration chamber. During the chamber
stays with the high-fat treatments, etomoxir or placebo was
administered in 5 doses (600 mg etomoxir in total). Blood sam-
ples were obtained on the mornings of days 4 and 5 of each treat-
ment, and appetite profiles were assessed.
Results: Mean (±SE) 24-h respiratory quotients were signifi-
cantly (P < 0.05) higher with repeated administrations of etomoxir
(0.833 ± 0.004) than with repeated administrations of placebo
(0.814 ± 0.006), and mean (±SE) 24-h whole-body fat oxidation
tended to be less (13.7%, P = 0.06) with administration of eto-
moxir (136.0 ± 5.2 g/d) than with administration of placebo
(157.5 ± 5.6 g/d). With the etomoxir treatment, fat balance was
positive (P < 0.0001) and carbohydrate balance was negative
(P < 0.001), whereas with the placebo treatment, neither of the
balances was significantly different from zero. Hunger and sati-
ety ratings were not affected under these conditions.
Conclusions: Etomoxir decreased whole-body fat oxidation, as
indicated by the respiratory quotients in the healthy subjects.
With the current protocol, however, hunger and satiety ratings
were not affected. Am J Clin Nutr 2002;76:141–7.
KEY WORDS Hepatic fatty acid oxidation, respiration
chamber, macronutrient composition, obesity, etomoxir
INTRODUCTION
Obesity is a major health concern in industrialized countries.
The high fat content of Western diets has been related to
increased voluntary energy intake and an increasing body mass
index in susceptible individuals (1–3). The high palatability of
high-fat foods makes overeating more likely (4), and the high
energy density of fat-rich diets has been shown to increase
energy intake in animals (5) and humans (6, 7), probably related
to decreased total food weight (passive overeating). Further-
more, subjects who are obesity prone seem to have more diffi-
culty than do subjects who are not adjusting their fat oxidation
when switched from a low- to a high-fat diet; this difficulty
favors fat storage. For example, fat oxidation in formerly obese
women failed to increase appropriately after a 3-d adaptation to
a 50% fat diet, whereas in normal-weight control subjects, fat
oxidation increased sufficiently to match fat intake (8). These
results suggest that the partitioning of fat between storage and
oxidation is important in the development of obesity in subjects
who consume a high-fat diet.
The oxidation of fuels, including fatty acids, has been impli-
cated in metabolic satiety. Evidence for a role of metabolic sati-
ety signals in food intake control comes from animal studies that
indicate that eating is inversely related to the rate of fuel utiliza-
tion (9–12). The liver is one likely location where fuel oxidation
is probably monitored and translated into a neural signal for the
brain. According to current thinking, high oxidative metabolism
in the liver signals the presence of sufficient energy-yielding
substrates and suppresses food intake. In particular, fatty acid
oxidation in the liver seems to act as a satiety signal. Ingestion
or intragastric administration of medium-chain fatty acids,
which are easily taken up and rapidly oxidized by liver cells, has
been shown to inhibit eating in animals (13, 14) and humans
(15, 16). Furthermore, different inhibitors of fatty acid oxidation
have been shown to increase food intake in rats and mice adapted
to a high-fat diet (17, 18). One way to inhibit fatty acid oxidation
is by blocking carnitine O-palmitoyltransferase I (EC 2.3.1.21;
CPT-I), the rate-limiting enzyme in the transport of long-chain
Am J Clin Nutr 2002;76:141–7. Printed in USA. © 2002 American Society for Clinical Nutrition
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fatty acids into the mitochondrion, where -oxidation takes
place. We recently showed that a single dose of the CPT-I
inhibitor etomoxir increases food intake in healthy young men
who habitually consume a high-fat diet (19). Etomoxir decreased
the plasma concentration of -hydroxybutyrate (BHB) and
hence hepatic fatty acid oxidation, but we did not detect a
decrease in whole-body fat oxidation, measured during 200 min
by indirect calorimetry with the use of a ventilated hood system.
In the present study, we used a respiration chamber to meas-
ure 24-h substrate oxidation after adaptation to a high- or low-fat
diet. We measured changes in substrate oxidation and satiety rat-
ings in response to repeated administrations of etomoxir in sub-
jects who consumed a high-fat diet. We hypothesized that, under
these conditions, administration of etomoxir would decrease
whole-body and hepatic fatty acid oxidation and satiety.
SUBJECTS AND METHODS
Subjects
Ten healthy, lean, young men with a mean (± SE) body mass
index (in kg/m2) of 21.8 ± 0.3, a mean (± SE) percentage of
body fat of 12.5 ± 1.46%, and a mean (± SE) age of 25.6 ± 1.7 y
participated in the study. The men were recruited by advertise-
ments. The Medical Ethics Committee of the University of
Maastricht approved the study, and subjects gave their written,
informed consent.
Experimental design
Each subject underwent 3 different treatments in randomized
order. Each treatment lasted for 5 d. Subjects ate either a low-
fat diet (LF-control treatment) or a high-fat diet. We used the
low-fat diet as a positive control, because from previous stud-
ies we know that substrate oxidation with a low-fat diet is dif-
ferent from that with a high-fat diet. With the high-fat diet, sub-
jects were given either etomoxir (HF-etomoxir treatment) or
placebo (HF-placebo treatment). Etomoxir was purchased from
HPO Wolf (Projekt Entwicklung GmbH, Allensbach, Ger-
many). All treatments started with a 3-d prefeeding period of
the low- or high-fat diet at home (days 1–3). On the evening of
day 3, subjects entered the respiration chamber for a 36-h stay.
During the stay in the chamber, etomoxir or placebo was given
in 5 doses: 1 capsule (75 mg etomoxir) on each of the evenings,
2 capsules (150 mg) on each of the mornings, and 2 capsules
(150 mg) on the afternoon of day 4. This resulted in a total eto-
moxir dose of 600 mg over the 36 h in the respiration cham-
ber. The last dose of 150 mg on the morning of day 5 was
administered in accordance with a second part of the experi-
ment, which consisted of a muscle biopsy; the muscle biopsy
specimens are still being analyzed.
During the HF-placebo treatment, subjects followed the same
time schedule with the same amount of capsules, but the cap-
sules did not contain any drug. During the LF-control treatment,
no capsules were given.
During day 4, the subjects completed a 100-mm visual ana-
logue scale (VAS) 10 times: before and after each main meal; in
the course of the morning, the afternoon, and the evening; and
before going to bed. These scales provided ratings of the sub-
jects’ perceptions of hunger and satiety (20). Blood samples
were taken in the morning on days 4 and 5. The subjects left the
respiration chamber on the morning of day 5.
Diets
The metabolizable energy and macronutrient composition of
the diet were calculated by using the Dutch food composition
table (21). In this table, metabolizable energy is calculated by
multiplying the amounts of protein, fat, and carbohydrate with
the respective Atwater factors (16.74, 37.66, and 16.74 kJ/g).
The high-fat diet contained 60% of energy as fat, 30% as carbo-
hydrate, and 10% as protein. The low-fat diet contained 10% of
energy as fat, 60% as carbohydrate, and 30% as protein (20).
Because milk fat contains a high amount medium-chain fatty
acids, it was excluded from the high-fat diet. This ensured that
mainly long-chain fatty acids contributed to the fat content of the
high-fat diet. The high- and low-fat diets provided in the cham-
ber did not differ significantly in mean (± SE) palatability, as
measured by the VAS (72.6 ± 2.7 and 71.1 ± 5.2 mm for the high-
and low-fat diets, respectively). The 2 diets were closely
matched in flavor and did not differ significantly in mean (± SE)
energy density (5.4 ± 0.2 and 5.2 ± 0.1 kJ/g for the high- and
low-fat diets, respectively). Diets in the chamber were consumed
as breakfast, lunch, dinner, and evening snack. The food quotient
(FQ) was defined as the ratio of carbon dioxide produced to oxy-
gen consumed during the oxidation of a representative sample of
the diet consumed (22).
For days 1 and 2 and the first part of day 3, the diet (either
low- or high-fat) was provided for consumption at home. Sub-
jects were given a fixed amount of food (1.65 times the basal
metabolic rate, based on the Harris and Benedict equation
BMR = 0.28 + (2.093  H) + (0.058  BM) 
 (0.028  A) (1)
where BMR is the basal metabolic rate in MJ/d, H is height in m,
BM is body mass in kg, and A is age in years (23). On the
evening of day 3, subjects consumed their dinner and evening
snack in the respiration chamber. On day 4, subjects were given
an amount of energy equal to 1.55 times the sleeping metabolic
rate (SMR), as measured during the preceding night. In a previ-
ous study with a comparable activity protocol in the chamber,
this same physical activity index of 1.55 was reached (24).
Procedures
Body composition
The subjects’ whole-body density was determined by weigh-
ing them underwater in the morning while they were fasting.
Body weight was measured on a digital balance (E1200; Sauter,
Albstadtl-Ebingen, Germany) with an accuracy of 0.01 kg. Lung
volume was measured simultaneously by the helium dilution
technique with the use of a spirometer (Volugraph 2000; Mijn-
hardt, Bunnik, Netherlands). Percentage of body fat was calcu-
lated by using the equations of Siri (25).
Indirect calorimetry and physical activity
Oxygen consumption and carbon dioxide production were
measured in a respiration chamber (26). The respiration chamber
is a 14-m3 room furnished with a bed, chair, television, radio,
telephone, computer with internet connection, intercom, wash bowl,
and toilet. The room was ventilated with fresh air at a rate of
70–80 L/min. The ventilation rate was measured with a dry gas
meter (G6; Schlumberger, Dordrecht, Netherlands). The concen-
trations of oxygen and carbon dioxide were measured by using a
paramagnetic oxygen analyzer (Magnos G6; Hartmann & Braun,
Frankfurt, Germany) and an infrared carbon dioxide analyzer
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(Uras 3G; Hartmann & Braun). Ingoing air was analyzed once
every 15 min and outgoing air once every 5 min. The gas sample
to be measured was selected by a computer that also stored and
processed the data. Energy expenditure was calculated from oxy-
gen consumption and carbon dioxide production according to the
method of Weir (27).
In the respiration chamber, subjects followed an activity pro-
tocol consisting of fixed times for breakfast, lunch, and dinner;
sedentary activities; and bench-stepping exercise. The bench-
stepping exercise was performed 3 times daily for 30 min each
time. Each performance of the exercise consisted of 5-min peri-
ods of exercise alternated with 5-min periods of rest. The exer-
cises were performed at a rate of 60 steps/min, and the bench
height was 33 cm. Thus, subjects exercised for 45 min/d at low-
to-medium intensity. Throughout the daytime, no sleeping or
other exercise was allowed during the stay in the respiration
chamber. All physical activity of the subjects was monitored by
means of a radar system based on the Doppler principle.
Urinary nitrogen excretion
During the subjects’ stay in the respiration chamber, urine was
collected in 2 batches, one from 2000 to 0800 and one over the
subsequent 24-h interval. Subjects were requested to empty their
bladders at 0800. The urine produced was included in the urine
sample of the previous batch. Samples were collected in con-
tainers with 10 mL H2SO4 to prevent nitrogen loss through evap-
oration; the volume and nitrogen concentration of the samples
were measured; the latter was measured by using a nitrogen ana-
lyzer (CHN-O-Rapid; Carlo-Erba, Hanau, Germany).
Twenty-four-hour energy expenditure, substrate oxidation, and
sleeping respiratory quotient
Subjects stayed in the respiration chamber for 36 h. For cal-
culating balances, 24-h energy expenditures and 24-h respiratory
quotients (RQs) were measured from 0800 on day 4 to 0800 on
day 5. The sleeping RQ was defined as the RQ measured from
0030 to 0700. The SMR was defined as the lowest mean energy
expenditure measured during 3 consecutive hours between 0000
and 0800 with a minimal activity level as indicated by the radar
system. Carbohydrate, fat, and protein oxidation were calculated
by using oxygen consumption, carbon dioxide production, and
urinary nitrogen losses with the equations of Brouwer (28)
Protein oxidation (g/d) = 6.25  N (2)
Fat oxidation (g/d) = (1.718  ·VO2)  (1.718 
·
VCO2) 
 (0.315  P) (3)
Carbohydrate oxidation (g/d) = (4.17  ·VCO2)  (2.965 

·
VO2)  (0.390  P) (4)
where N is the total nitrogen excreted in urine (g/d), ·VO2 is the
oxygen consumption (L/d), ·VCO2 is the carbon dioxide produc-
tion (L/d), and P is protein oxidation (g/d).
Dietary restraint
A Dutch translation of the 3-factor eating questionnaire (TFEQ)
of Stunkard and Messick (20, 29) was used to discriminate between
“cognitive restrained” and “unrestrained” eaters. If factor 1 of the
3-factor eating questionnaire was not >9, subjects were considered
to be unrestrained eaters. We previously showed that the subject
population that is used in the Department of Human Biology at the
University of Maastricht has a median factor 1 score of 9 (30).
According to these criteria, 9 of the 10 subjects who participated in
the present study qualified as unrestrained eaters.
Satiety scores
At 10 fixed time points on day 4 (before, after, and in between
the main meals), a 100-mm VAS was completed to quantify the
perceptions of satiety, hunger, fullness, and desire to eat. After
meals, a VAS was included to quantify the palatability of the meal.
From the 10 ratings between 0930 and 2300, the area under
the curve was calculated (20). To complete the area under the
curve over 24 h, VAS ratings were interpolated from the last
measurement at night until the first measurement in the morn-
ing (20). One subject who qualified as a restrained eater accord-
ing to the criteria described above was excluded from the analy-
sis of satiety ratings.
Blood analyses
With all 3 treatments, blood samples were taken on the morn-
ing of days 4 and 5 after an overnight fast. For the blood collec-
tion on day 4, subjects put their arm through an air lock in the
chamber wall, which has a rubber sleeve to fit around the upper
arm and is positioned under a window for eye contact. This
allowed for blood sampling without disruption of the respiration
chamber measurements. Samples of venous blood (10 mL) were
obtained in EDTA-coated tubes and immediately centrifuged at
high speed for 10 min (1000  g, 4 C). Plasma was frozen in
liquid nitrogen and stored at 80 C until analyzed for glucose
(hexokinase method, Roche, Basel, Switzerland), fatty acids
(Wako NEFA C test kit, Wako Chemicals, Neuss, Germany), lac-
tate (31), BHB (32), and glycerol and triacylglycerols (glycerol
kinase-lipase method, Boehringer Mannheim, Mannheim, Ger-
many) on a COBAS BIO analyzer (COBAS FARA semi-automatic
analyzer, Roche, Basel, Switzerland).
Statistical analysis
All data are presented as means ± SE. To detect treatment dif-
ferences, treatments were analyzed pairwise with t tests. To
compensate for this procedure, P values were multiplied by a
Bonferroni correction factor of 3.
A two-factor repeated-measures analysis of variance with
interactions was used to detect treatment  time interactions in
selected variables. When significant differences were found, a
Bonferroni-adjusted post hoc test was used to determine the
exact location of the difference.
One subject underwent only the HF-etomoxir and the
HF-placebo treatments, and thus his data could not contribute to
the results analyzed by a two-factor repeated-measures analysis
of variance. Therefore, the results that were analyzed with a two-
factor analysis of variance are based on only 9 subjects. The
analysis of the satiety ratings is also based on 9 subjects.
We used the statistics programs STATVIEW SE + GRAPHICS
(Abacus Concepts, Inc, Berkeley, CA) and SPSS for WINDOWS
release 10.0.0 (SPSS Inc, Chicago). Outcomes were regarded as
statistically significant if P < 0.05.
RESULTS
Substrate oxidation
With the HF-etomoxir treatment, 24-h RQs were significantly higher
than with the HF-placebo treatment (P < 0.05). Twenty-four-hour
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RQs were significantly higher with the LF-control diet than with
the HF-placebo (P < 0.0005) or the HF-etomoxir treatments
(P < 0.005) (Figure 1).
There was a significant treatment effect and time  treatment
interaction effect on sleeping RQs (P < 0.05). With the LF-
control treatment, sleeping RQs were significantly higher than
with the HF-placebo treatment during both nights (P < 0.0005),
and the changes in sleeping RQ from night 1 to night 2 differed
significantly between the HF-etomoxir and the LF-control treat-
ments (P < 0.05). Sleeping RQs did not differ significantly
between the HF-etomoxir and HF-placebo treatments during the
first night, but during the second night, sleeping RQs were signi-
ficantly higher with the HF-etomoxir treatment than with the
HF-placebo treatment (P < 0.05) (Figure 2).
Whole-body fat oxidation tended to be inhibited by etomoxir
and was 13.7% less than with the HF-placebo treatment
(P = 0.06), whereas carbohydrate oxidation tended to be con-
comitantly increased with etomoxir (P = 0.08). Protein oxida-
tion was not significantly different between the HF-etomoxir and
HF-placebo treatments. Fat oxidation was significantly lower with
the LF-control treatment than with the HF-placebo (P < 0.0005) or
HF-etomoxir treatments (P < 0.001). Carbohydrate oxidation, on
the other hand, was higher with the LF-control treatment than
with the HF-etomoxir (P < 0.05) or the HF-placebo treatments
(P < 0.001). Protein oxidation was significantly higher with the
LF-control treatment than with the HF-etomoxir (P < 0.0005) or
HF-placebo treatments (P < 0.0005) (Figure 3). FQs were signi-
ficantly different from RQs with the HF-etomoxir treatment
(FQ = 0.803 ± 0.000, RQ = 0.833 ± 0.004, P < 0.001) and the
LF-control treatment (FQ = 0.907 ± 0.001, RQ = 0.887 ± 0.006,
P < 0.05) but not with the HF-placebo treatment (FQ = 0.803 ± 0.000,
RQ = 0.814 ± 0.006, P > 0.05).
For all 3 treatments, the energy balance was not significantly
different from zero. With the HF-etomoxir treatment, the carbo-
hydrate balance was negative (P < 0.001), the fat balance was
positive (P < 0.0001), and the protein balance was not signifi-
cantly different from zero. With the HF-placebo treatment, none
of the macronutrient balances was significantly different from
zero. With the LF-control treatment, the fat balance was negative
(P < 0.01), whereas there was a tendency toward a positive car-
bohydrate balance (P = 0.07) and the protein balance was posi-
tive (P < 0.05) (Figure 4).
Energy expenditure
Twenty-four-hour energy expenditures were not significantly
different between the treatments (11.455 ± 0.27, 11.182 ± 0.30,
and 11.007 ± 0.28 MJ/d for the LF-control, HF-placebo, and
HF-etomoxir treatments, respectively; P > 0.05). There was no
treatment effect, but there was a time  treatment interaction effect
on SMR measured during the 2 nights. With the HF-etomoxir
144 HINDERLING ET AL
FIGURE 1. Comparison of mean (± SE) 24-h respiratory quotients
(RQs) during the 3 treatments: low-fat (LF)-control, high-fat (HF)-
placebo, and HF-etomoxir. *Significantly different from HF-etomoxir
and HF-placebo, P < 0.005 (paired t test with Bonferroni correction;
n = 9). **Significantly different from HF-etomoxir, P < 0.05 (paired t test
with Bonferroni correction; n = 10).
FIGURE 2. Comparison of mean (± SE) sleeping RQs during the
2 consecutive nights between the treatments [low-fat (LF)-control (),
high-fat (HF)-placebo (), and HF-etomoxir ( )]. There were signifi-
cant treatment effects and time  treatment interaction effects (P < 0.05)
by two-factor repeated-measures ANOVA. *Significantly different from
HF-placebo on night 1, P < 0.05 (n = 9). **Significantly different from
HF-placebo on night 2, P < 0.005 (n = 9). ***Significantly different
from HF-placebo on night 2, P < 0.005, and from HF-etomoxir on night 1,
P < 0.05 (n = 9).
FIGURE 3. Comparison of mean (±SE) macronutrient oxidation between
the 3 treatments [low-fat (LF)-control (), high-fat (HF)-placebo (), and
HF-etomoxir ( )]. *Significantly different from HF-etomoxir and
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treatment, SMRs were significantly lower than with the LF-
control treatment during the second night (P < 0.05; night 1:
7.13 ± 0.16 compared with 7.19 ± 0.17 MJ/d; night 2: 6.99 ± 0.13
compared with 7.33 ± 0.13 MJ/d).
Blood parameters
There was a significant treatment effect for plasma glucose
(P < 0.05), but no significant differences were observed between the
HF-etomoxir and HF-placebo treatments. Plasma glucose was lower
with the LF-control treatment than with the HF-placebo treatment.
There were no significant treatment effects or time  treatment
interaction effects for plasma lactate, BHB, and glycerol concen-
trations. There was also no treatment effect for fatty acids, but
there was a time  treatment effect: fatty acid concentrations
increased significantly more with the HF-etomoxir treatment than
with the HF-placebo treatment (P < 0.05). There was also a treat-
ment effect for triacylglycerol concentration, with significantly
lower concentrations with the HF-etomoxir treatment than with
the HF-placebo treatment and lower concentrations with the
HF-placebo treatment than with the LF-control treatment.
(P < 0.0001). There was no significant time  treatment effect
(Table 1). The individual differences in BHB between the HF-
etomoxir and HF-placebo treatments on day 4 correlated with the
differences in 24-h RQs between the 2 treatments (r2 = 0.72, P < 0.005).
Satiety ratings
The 24-h satiety and hunger scores (area under the curve)
were not significantly different between the 3 treatments (data
not shown). The hunger and satiety ratings did not differ signifi-
cantly at any time point during the day (Table 2).
DISCUSSION
In the present study, we found that the repeated administration
of the CPT-I blocker etomoxir increased 24-h RQs and tended to
decrease 24-h whole-body fat oxidation but did not affect hunger
and satiety ratings in healthy men. Although it has been shown
previously that etomoxir increases RQs in type II diabetic subjects
(33), to our knowledge this is the first time that an increase in 24-h
RQs because of etomoxir has been observed in healthy humans.
In our previous study, the increase in RQs did not reach signi-
ficance over 200 min after a single dose of etomoxir (19). In the
present study, the sleeping RQ during the second night of the
HF-etomoxir treatment was significantly higher than that dur-
ing the first night, whereas there was no difference between the
2 nights in sleeping RQs with the placebo treatment. This indi-
cates that the repeated administration of etomoxir resulted in a
gradual decrease of whole-body fat oxidation, which might
explain why we did not observe an effect on the RQ after a sin-
gle dose of etomoxir in our previous study (19).
In the present study, we fed subjects either a low- or high-fat
diet for 3 d at home and for 1 d in the respiration chamber to
reach a state of substrate balance. However, even after 4 d of
adaptation to the low-fat diet, the RQ and the FQ still differed
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FIGURE 4. Comparison of mean (± SE) energy ( ), carbohy-
drate (), fat (), and protein ( ) balances during the 3 treatments
[low-fat (LF)-control (n = 9), high-fat (HF)-placebo (n = 10), and
HF-etomoxir (n = 10)]. *Significantly different from zero, P < 0.05.
TABLE 1
Fasting blood concentrations during the 3 treatments, measured in the morning on days 4 and 51
Day LF-control HF-placebo HF-etomoxir
Glucose (mmol/L)2,3 4 4.59 ± 0.10 4.82 ± 0.07 4.89 ± 0.15
5 4.61 ± 0.11 4.84 ± 0.13 4.60 ± 0.14
Lactate (mmol/L) 4 0.66 ± 0.08 0.76 ± 0.09 0.80 ± 0.09
5 0.95 ± 0.12 0.98 ± 0.12 0.98 ± 0.08
BHB (mol/L) 4 158.4 ± 12.1 191.5 ± 16.2 169.3 ± 20.3
5 204.3 ± 16.7 205.2 ± 8.3 203.1 ± 20.0
Glycerol (mol/L) 4 47.7 ± 4.9 64.0 ± 8.5 59.2 ± 12.9
5 92.7 ± 14.6 100.8 ± 25.2 88.7 ± 10.7
Fatty acids (mol/L)4 4 185.9 ± 21.5 284.5 ± 37.1 219.9 ± 39.2
5 401.7 ± 55.6 381.5 ± 44.1 487.4 ± 75.6
Triacylglycerol (mol/L)2,5 4 1200.6 ± 203.5 677.2 ± 142.7 651.5 ± 166.5
5 1154.2 ± 166.7 733.3 ± 131.6 416.4 ± 96.5
1 x– ± SE; n = 9. LF, low-fat; HF, high-fat; BHB, -hydroxybutyrate.
2 Significant treatment effect, P < 0.05 (two-factor repeated-measures ANOVA).
3 The LF-control treatment was significantly different from the HF-placebo treatment, P < 0.05 (Bonferroni-adjusted post hoc test).
4 Significant time  treatment effect, P < 0.05 (two-factor repeated-measures ANOVA). There was a significantly larger increase with the HF-etomoxir
treatment than with the HF-placebo treatment, P < 0.05 (Bonferroni-adjusted post hoc test).
5 The HF-etomoxir treatment differed significantly from the HF-placebo treatment and the HF-placebo treatment differed significantly from the LF-control
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significantly, indicating that the adaptation was not completely
achieved. Earlier studies with carbohydrate diets reported similar
results (3). Hill et al (34) found that even after 7 d of a high-
carbohydrate diet adaptation was not completely achieved, whereas
subjects on a high-fat diet showed a smaller difference between
the RQ and the FQ. With the HF-placebo treatment, the subjects’
RQ was not significantly different from their FQ, showing that fat
oxidation had adapted to the high-fat diet within 4 d. This is in
accordance with our previous results, indicating that adaptation
of fat oxidation to a high-fat diet is accomplished within 3–7 d (35).
With the HF-etomoxir treatment of the present study, the RQ was
significantly higher than the FQ, revealing that etomoxir partly
reversed the adaptive increase in fat oxidation.
With respect to triacylglycerol concentrations, clomoxir, which
also inhibits CPT-I, has been shown to increase plasma triacyl-
glycerols acutely and to have a triacylglycerol-lowering effect
when administered chronically (36). Accordingly, we found an
increase in plasma triacylglycerols after a single administration of
etomoxir in our earlier study, whereas in the present study, after
repeated administration, we observed a decrease in plasma triacyl-
glycerol concentrations. Chronic administration of clomoxir has
been shown to increase cardiac lipoprotein lipase activity and post-
heparin plasma lipoprotein lipase, which leads to an increased
clearance of triacylglycerols from plasma (37). Such a mechanism
may also be responsible for the triacylglycerol-lowering effect of
etomoxir reported here.
The plasma concentration of BHB can be used as an indicator
of hepatic fatty acid oxidation and is therefore especially inter-
esting when studying the effect of hepatic fatty acid oxidation on
satiety. However, in contrast to our previous observation after a
single administration of etomoxir (19), plasma BHB was, on
average, not significantly affected by repeated administration of
etomoxir in the present study. However, individual differences in
BHB between the etomoxir and placebo treatments on day 4
were strongly correlated with the difference in 24-h RQs
between the 2 treatments. Therefore, our results are consistent
with a suppressive effect of etomoxir on hepatic fatty acid oxi-
dation, but there seems to be a large interindividual variability in
this effect. It is also possible that the inhibition of hepatic fatty
acid oxidation by etomoxir is more pronounced in the acute than
in the chronic situation, where adaptational changes in response
to inhibition of CPT-I might occur.
The absence of a general effect of repeated etomoxir adminis-
tration on plasma BHB on days 4 and 5 is in agreement with the
absence of an effect of etomoxir on hunger. Yet, it should also be
considered in this context that hunger and satiety ratings do not
always correspond exactly to actual food intake (15). To keep
subjects in energy balance, we provided them with a fixed diet,
which made it impossible to measure ad libitum food intake.
Furthermore, in our earlier study subjects were selected who
habitually ate a high-fat diet, reflecting a population who is
adapted to a high-fat diet for a long time and who might be con-
ditioned to rely on hepatic fatty acid oxidation as a satiety factor.
Although the subjects in the present study were adapted in terms
of whole-body substrate oxidation, other adaptations such as
conditioning might only occur during a longer term.
Protein and carbohydrate have been shown to be oxidized
before fat, and accordingly, a hierarchy in satiety has been
described in which protein and carbohydrate are more satiating
than is fat (38). We confirmed these findings in a previous study,
showing that 24-h satiety ratings in healthy women were lower
when a high-fat diet was consumed than when a high-protein–
high-carbohydrate diet was consumed (20). In the present
study, we used diets with the same macronutrient composition
as in the previous study (20), but this time with a 3-d adapta-
tion period at home. In this setting, the subjects were adapted
to the high-fat diet and to the low-fat diet. Thus, it was possi-
ble to examine the effect of substrate oxidation in an adapted
rather than in an acute situation, and under these conditions we
could not detect any difference in 24-h satiety between the
high-fat and low-fat diets.
In conclusion, we found a clear effect of repeated etomoxir
administration on whole-body substrate oxidation, and our
results suggest that hepatic fatty acid oxidation also may be
inhibited by etomoxir. However, under the current conditions,
we did not find an effect on hunger and satiety ratings. The
results show that the acute effects of etomoxir cannot be com-
pletely extrapolated to the longer term and emphasize the
importance of a period of long adaptation to dietary fat for
effects on satiety.
We thank Riemer Renkema and Manuela Lejeune for their help in perform-
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and Kathleen Melanson for reviewing the English version of the manuscript.
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TABLE 2
Hunger and satiety ratings on a 100-mm visual analogue scale1
Hunger Satiety
LF-control HF-placebo HF-etomoxir LF-control HF-placebo HF-etomoxir
Before breakfast 63.5 ± 7.4 70.9 ± 4.3 75.9 ± 5.4 34.0 ± 9.5 25.4 ± 6.3 21.7 ± 5.4
After breakfast 18.2 ± 4.9 31.6 ± 7.6 32.8 ± 10.4 70.4 ± 7.8 53.4 ± 9.0 60.3 ± 11.2
During the morning 42.2 ± 6.7 60.5 ± 9.02 38.1 ± 10.8 51.7 ± 7.5 21.4 ± 8.42 41.2 ± 10.0
Before lunch 77.7 ± 4.7 72.6 ± 6.4 63.4 ± 7.4 25.2 ± 7.7 17.1 ± 3.8 26.4 ± 6.4
After lunch 19.9 ± 6.4 21.8 ± 6.7 22.3 ± 7.05 63.0 ± 11.8 72.8 ± 7.3 64.2 ± 8.7
During the afternoon 44.9 ± 9.0 44.8 ± 10.2 41.4 ± 10.2 40.4 ± 9.3 51.7 ± 9.2 49.0 ± 9.8
Before dinner 71.8 ± 5.5 84.3 ± 3.2 81.0 ± 7.1 21.0 ± 5.0 13.4 ± 2.7 18.8 ± 5.6
After dinner 22.6 ± 7.3 21.2 ± 5.8 18.4 ± 9.2 59.9 ± 11.2 72.2 ± 7.3 69.7 ± 12.43
During the evening 35.1 ± 8.83 44.7 ± 8.9 29.3 ± 9.4 55.3 ± 13.13 39.7 ± 8.1 52.4 ± 10.4
Before going to bed 45.3 ± 12.23 52.5 ± 9.8 31.2 ± 10.5 41.6 ± 13.63 36.1 ± 7.7 46.3 ± 9.7
1 x– ± SE; n = 9 except where indicated otherwise. LF, low-fat; HF, high-fat. There were no significant differences at any time point (repeated-
measures ANOVA).
2 n = 7.
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